2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Palliative Care, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Bacterial, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3340 Evolving risk classification without matching survival gains in childhood acute myeloid leukemia across sequential St. Jude AML02 and AML08 trials

Eesha A. Zaheer, MD, Zhaohan Zhu2, Huiyun Wu, PhD3, Norman Lacayo, MD4, Kenneth Heym Jr, MD5, Jeffrey W. Taub, MD6, Barbara Degar, MD7, Deborah Schiff, MD8, Brandon Triplett, MD9, Ching-Hon Pui, MD10, Raul Ribeiro, MD11, Jeffery M. Klco, Member; Director, Division of Hematopathology and Molecular Pathology12, Jeffrey Rubnitz, MD, PhD13, Stanley Pounds, PhD14, Hiroto Inaba, MD. PHD15
1 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
2 St. Jude Children's Research Hospital, Memphis, Tennessee, United States, University of Tennessee School of Medicine, Memphis, Tennessee, United States
3 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
4 Stanford University School of Medicine, Palo Alto, California, United States
5 Cook Children's Hospital, Fort Worth, Texas, United States
6 Wayne State University School of Medicine, Detroit, Michigan, United States
7 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts, United States
8 Rady Children’s Hospital, San Diego, California, United States, University of California School of Medicine, San Diego, California, United States
9 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
10 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
11 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
12 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
13 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
14 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
15 St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Introduction. Survival for children with acute myeloid leukemia (AML) has improved across successive treatment eras, attributed to better risk classification based on diagnostic genetics and measurable residual disease (MRD), allogeneic hematopoietic cell transplantation (HCT) for high-risk disease in first remission, and improved supportive care. Whether refinements in risk assignment between sequential trials were accompanied by greater transplant utilization and improved survival has not been directly examined. We compared risk classification, first-line HCT utilization, and outcomes across two sequential multi-institutional trials led by St. Jude Children’s Research Hospital, AML02 and AML08.

Methods. We analyzed 454 children and adolescents with de novo AML treated on AML02 (2002-2008; n=203) and AML08 (2008-2017; n=251). Both protocols used diagnostic genetics and induction treatment response (MRD was implemented in AML02) to assign risk and direct therapy; low-risk patients received chemotherapy alone, and high-risk patients were allocated to allogeneic HCT in first remission. Intermediate-risk patients were considered for HCT when matched sibling donors were available. Risk-group distribution and first-line HCT utilization were compared by the chi-square test. Three-year event-free survival (EFS) and overall survival (OS) based on risk-group and from the date of HCT, were estimated by the Kaplan-Meier method. All P values are 2-sided.

Results. Final risk classification shifted toward the intermediate-risk category between eras: low-risk fell from 33.0% to 20.7% while intermediate-risk rose from 33.5% to 43.4% and high-risk was stable (33.5% to 35.9%), reflecting broader molecular characterization and MRD-based reclassification of some patients into the intermediate group. Molecular characterization increased from 80.8% to 89.6% (AML02 to AML08; P=.01). First-line HCT utilization was numerically higher on AML08 (24.1% vs 29.1%; P=.28); transplants were concentrated in high-risk patients in both eras (77.6% vs 79.5% of transplants), with no significant association between risk group and trial (P=.34). Despite refined risk assignment, 3-year survival did not improve within any risk group (AML02 vs AML08, respectively): low-risk (EFS 82.0% [95% CI, 73.3-91.8] vs 86.2% [77.2-96.3], P=.50; OS 89.3% [82.2-97.1] vs 96.2% [91.1-100.0], P=.18), intermediate-risk (EFS 63.2% [52.8-75.8] vs 56.5% [47.7-66.8], P=.49; OS 73.5% [63.8-84.8] vs 72.5% [64.4-81.6], P=.57), and high-risk (EFS 42.6% [32.3-56.2] vs 41.9% [32.8-53.5], P=.95; OS 52.1% [41.4-65.6] vs 55.7% [46.2-67.2], P=.73). Outcomes after transplant were likewise unchanged (post-HCT EFS 56.5% [43.3-73.9] vs 55.3% [44.4-68.9], P=.88; OS 60.8% [48.4-76.2] vs 57.5% [47.0-70.3], P=.76), as was survival among chemotherapy-only patients (low-risk OS 88.9% [81.4-97.0] vs 96.1% [90.9-100.0], P=.17; intermediate-risk OS 71.7% [61.1-84.0] vs 74.1% [65.7-83.6], P=.87). Among post-HCT relapses with molecular data (n=28; 9 on AML02, 19 on AML08), KMT2A-rearranged and NUP98-rearranged genotypes were over-represented, together accounting for 10 (35.7%): KMT2A-rearranged, n=6; NUP98-rearranged, n=4.

Conclusions. Across two sequential pediatric AML trials, refinement of risk classification with improved molecular characterization and incorporation of MRD were not accompanied by significant gains in survival, and the outcomes within every risk group, and after HCT, plateaued between eras. These data indicate that incremental refinement of conventional risk-directed chemotherapy and transplantation alone are necessary but not sufficient to further improve outcomes and support integration of novel targeted (eg, menin inhibitors [revumenib], FLT3 inhibitors [gilteritinib], BCL2 inhibitors [venetoclax]) and immunotherapeutic (eg, chimeric antigen receptor therapy) agents and epigenetic priming strategies now under prospective evaluation. The over-representation of KMT2A- and NUP98-rearranged disease among post-transplant relapses further nominates these menin-dependent alterations involving HOX cluster genes as priority targets for such approaches.

Eesha A. Zaheer, MD: No relevant conflicts of interest to declare.